journal article·2025-07

Inflammation-targeted delivery of probiotics for alleviation of colitis and associated cognitive disorders through improved vitality and colonization

Yi Chen, Mingju Shui, Hongyi Li, Miao Guo, Qin Yuan, Wei Hao, Tao Wang, Hefeng Zhou, Zhejie Chen, Shengpeng Wang

Biomaterials· Volume 318
Publisher page

Abstract

Oral probiotic biotherapies hold significant promise for addressing intestinal inflammatory disorders. Nonetheless, due to the challenging pathological microenvironment of the gastrointestinal tract, it is difficult to achieve deliver probiotics in an inflammation-targeted manner while improving their intestinal colonization and minimizing the impact of gastrointestinal environment on their vitality. To address this, an innovative probiotics oral delivery system (EcN-Apt@HG) against ulcerative colitis (UC) was developed by conjugating IL-6 aptamer to the surface of EcN and subsequently encapsulating the probiotics in a hydrogel consisting of aldehyde-functionalized chondroitin sulfate (CS) and Poly(amidoamine) (PAMAM). As expected, the encapsulated EcN demonstrated resistance to gastrointestinal conditions, and the colonization duration of probiotics in the colon was enhanced via the preferential adhesion effect of IL-6 aptamer on the inflammatory site. The EcN-Apt@HG system restored the damaged mucosal layer, suppressed hyperactive immune responses, and reshaped the dysbiosis of intestinal microflora, thereby synergistically alleviating dextran sulfate sodium (DSS)-induced colitis. Notably, EcN-Apt@HG significantly alleviated depression-like behaviors and cognitive impairment in colitis mice through gut-brain axis interaction. This approach provides a simple and promising strategy for inflammation-targeted delivery of probiotics to the intestine and shows great potential for UC therapy and associated cognitive disorders.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Gut microbiota and health · Probiotics and Fermented Foods · Gastrointestinal motility and disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (51)

Show source-provided references
1. Unfermented β-fructan fibers fuel inflammation in select inflammatory bowel disease patients10.1053/j.gastro.2022.09.034 ↗
2. Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis10.1038/s41565-023-01346-x ↗
3. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease10.1126/science.aad9948 ↗
4. A gas therapy strategy for intestinal flora regulation and colitis treatment by nanogel‐based multistage NO delivery microcapsules10.1002/adma.202309972 ↗
5. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease10.1126/scitranslmed.aaa5657 ↗
6. The four epidemiological stages in the global evolution of inflammatory bowel disease10.1038/s41575-020-00360-x ↗
7. Redox-active nanoparticles for inflammatory bowel disease10.1007/s12274-021-3303-5 ↗
8. Oral polyphenol-armored nanomedicine for targeted modulation of gut microbiota–brain interactions in colitis10.1126/sciadv.adf3887 ↗
9. Wielding the double-edged sword: redox drug delivery systems for inflammatory bowel disease10.1016/j.jconrel.2023.05.007 ↗
10. Anxiety but not depression predicts poor outcomes in inflammatory bowel disease10.1093/ibd/izy385 ↗
11. Bi-directionality of brain–gut interactions in patients with inflammatory bowel disease10.1053/j.gastro.2018.01.027 ↗
12. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases10.1097/MIB.0000000000000620 ↗
13. The influence of the brain–gut axis in inflammatory bowel disease and possible implications for treatment10.1016/S2468-1253(19)30089-5 ↗
14. Impact of microbial metabolites on microbiota–gut–brain axis in inflammatory bowel disease10.3390/ijms22041623 ↗
15. Glutamatergic signaling along the microbiota-gut-brain axis10.3390/ijms20061482 ↗
16. The microbiota-gut-brain axis10.1152/physrev.00018.2018 ↗
17. Targeted delivery of the probiotic Saccharomyces boulardii to the extracellular matrix enhances gut residence time and recovery in murine colitis10.1038/s41467-024-48128-0 ↗
18. Advances in Escherichia coli Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies10.1016/j.mtbio.2023.100543 ↗
19. Advances in Escherichia coli Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies10.1016/j.mtbio.2023.100543 ↗
20. Aptamers as targeted therapeutics: current potential and challenges10.1038/nrd.2016.199 ↗
21. Aptamer-assisted tumor localization of bacteria for enhanced biotherapy10.1038/s41467-021-26956-8 ↗
22. Interleukin 6: biological significance and role in inflammatory bowel diseases10.17219/acem/130356 ↗
23. Oral chondroitin sulfate functionalized natural polyphenol for targeted therapy of ulcerative colitis10.1016/j.matdes.2024.112645 ↗
24. Cellulose nanocrystal reinforced collagen-based nanocomposite hydrogel with self-healing and stress-relaxation properties for cell delivery10.1021/acs.biomac.0c00345 ↗
25. Integrated cascade nanozyme catalyzes in vivo ROS scavenging for anti-inflammatory therapy10.1126/sciadv.abb2695 ↗
26. Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease10.1016/j.biomaterials.2022.121364 ↗
27. A proresolving peptide nanotherapy for site‐specific treatment of inflammatory bowel disease by regulating proinflammatory microenvironment and gut microbiota10.1002/advs.201900610 ↗
28. Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy10.1038/s41467-021-27463-6 ↗
29. Oral delivery of transformable bilirubin self‐assembled system for targeted therapy of colitis10.1002/adhm.202300946 ↗
30. Oral microsphere formulation of M2 macrophage-mimetic Janus nanomotor for targeted therapy of ulcerative colitis10.1126/sciadv.ado6798 ↗
31. Effect of Enterococcus faecalis 2001 on colitis and depressive-like behavior in dextran sulfate sodium-treated mice: involvement of the brain–gut axis10.1186/s12974-019-1580-7 ↗
32. Polyphenolic nanoparticle-modified probiotics for microenvironment remodeling and targeted therapy of inflammatory bowel disease
33. Brain-gut interactions in inflammatory bowel disease10.1053/j.gastro.2012.10.003 ↗
34. Inflammatory bowel disease: a stressed “gut/feeling”10.3390/cells8070659 ↗
35. IBD—what role do Proteobacteria play?10.1038/nrgastro.2012.14 ↗
36. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics10.1053/j.gastro.2004.03.024 ↗
37. Chlorogenic acid ameliorates experimental colitis by promoting growth of Akkermansia in mice10.3390/nu9070677 ↗
38. Sequence and cultivation study of Muribaculaceae reveals novel species, host preference, and functional potential of this yet undescribed family10.1186/s40168-019-0637-2 ↗
39. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease10.1016/S0016-5085(98)70019-8 ↗
40. Interactions between the microbiota and the immune system10.1126/science.1223490 ↗
41. Milk-derived extracellular vesicles alleviate ulcerative colitis by regulating the gut immunity and reshaping the gut microbiota10.7150/thno.62046 ↗
42. Metabolomic signatures distinguish the impact of formula carbohydrates on disease outcome in a preterm piglet model of NEC10.1186/s40168-018-0498-0 ↗
43. Modulation of the microbiota-gut-brain axis by probiotics in a murine model of inflammatory bowel disease10.1152/ajpgi.00086.2016 ↗
44. The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential10.1080/1040841X.2022.2044286 ↗
45. Brain–gut–microbiota axis—mood, metabolism and behaviour10.1038/nrgastro.2016.200 ↗
46. Versatility of bacterial outer membrane vesicles in regulating intestinal homeostasis10.1126/sciadv.ade5079 ↗
47. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD10.1038/s41575-019-0172-4 ↗
48. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease10.1038/s41575-019-0258-z ↗
49. Glycerophospholipid metabolism in the brain: a review
50. Long-term depression in the CNS10.1038/nrn2867 ↗
51. Bile acids: a communication channel in the gut-brain axis10.1007/s12017-020-08625-z ↗